Nov. 20, 2019: Alnylam Pharmaceuticals, the leading RNAi therapeutics company, announced the USFDA approved GIVLAARI™ (givosiran) injection (subcutaneous) for the treatment of adults with acute hepatic porphyria (AHP).
AHP is an exceptional, genetic diseases characterized by devitalizing, potentially life-threatening attacks and, for some patients, chronic manifestations that depressingly impact daily performance and quality of life.
Long-standing complications of AHP are chronic neuropathic pain, chronic kidney disease, hypertension and liver disease. GIVLAARI reduces the rate of porphyria attacks that required hospitalizations, urgent healthcare visits or IV hemin administration at home. http://investors.alnylam.com/news-releases/news-release-details/alnylam-announces-approval-givlaaritm-givosiran-us-food-and-drug
